Sorafenib is an oral multikinase inhibitor that blocks tumor cell proliferation by targeting Raf/MEK/ERK signalling pathway and that has an antiangiogenic effect by targeting vascular endothelial growth factor receptor [5, 6]. This evidence concerns the gene MAP2K7 and neoplasm.